Business

Market Movers

Myriad shares volatile on court ruling

A complex Supreme Court ruling at first drove Myriad shares to a four-year high.

AFP/GEtty Images

A complex Supreme Court ruling at first drove Myriad shares to a four-year high.

Advertisement

Shares of diagnostic test maker Myriad Genetics Inc. surged and then dove after the Supreme Court handed the company a partial victory in a battle over the validity of patents underlying its lucrative test for genes linked to high risk of breast and ovarian cancer. The Salt Lake City company sells a test for the BRCA 1 and BRCA 2 genes — the only test currently available because of its patents. They were challenged by a scientists group, leading to the Supreme Court’s review.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.